Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,630 JPY | +0.23% | +0.80% | +10.97% |
Apr. 08 | U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease | RE |
Apr. 03 | Kyowa Kirin Buys Back 4 Billion Yen Worth of Shares in March | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+10.97% | 9.03B | A- | ||
+5.31% | 69.91B | A | ||
-16.83% | 4.75B | A- | ||
+43.48% | 4.31B | - | ||
+3.20% | 3.88B | B- | ||
+18.82% | 2.37B | B | ||
-21.36% | 2.26B | C- | ||
-29.67% | 2.2B | - | ||
+8.38% | 1.98B | - | - | |
-0.50% | 1.64B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4151 Stock
- Ratings Kyowa Kirin Co. Ltd.